



Using Tele-Mentoring to Optimize Quality of Care and Quality of Life for Patients with Metastatic Kidney Cancer (TOQQ-RCC)



Session 1: Baseline Patient Assessment, Distress Screening

Articles:

- Annals of Oncology: [*Nivolumab + Cabozantinib vs Sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial*](#)
- IMDC: [*Prognostic Factors for Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-Targeted Agents: Results from a Large, Multicenter Study*](#)
- The Lancet Oncology: [*Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced cell carcinoma \(KEYNOTE-426\): extended follow-up from a randomized, open-label, phase 3 trial*](#)
- PubMed: [*Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma*](#)
- PubMed: [*Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma*](#)
- PubMed: [*The Prevalence of Psychological Distress by Cancer Site*](#)
- PubMed: [*Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma*](#)
- PubMed: [*Validation of the Distress Thermometer, Impact Thermometer and combinations of these in screening for distress*](#)

Resources:

National Comprehensive Cancer Network: [*Distress Management Guidelines*](#)